[1]
|
N. J. Wald and M. R. Law, “A Strategy to Reduce Cardiovascular Disease by More Than 80 Percent,” British Medical Journal, Vol. 326, No. 7404, 2003, p. 1419.
|
[2]
|
G. Sanz and V. Fuster, “Fixed-Dose Combination Therapy and Secondary Cardiovascular Prevention: Rationale, Selection of Drugs and Target Population,” Nature Clinical Practice Cardiovascular Medicine, Vol. 6, No. 2, 2009, pp. 101-110.
|
[3]
|
S. Yusuf, P. Pais, R. Afzal, et al., “Effects of a Polypill (Polycap) on Risk Factors in Middle-Aged Individuals without Cardiovascular Disease (TIPS): A Phase II, Double-Blind, Randomised Trial,” Lancet, Vol. 373, No. 9672, 2009, pp. 341-351.
|
[4]
|
M. R. Law and N. J. Wald, “Risk factor thresholds: their existence under scrutiny,” British Medical Journal, Vol. 324, No. 7353, 2002, pp. 570-576.
|
[5]
|
V. Kumar, R. P. Shah and S. Singh, “LC and LC-MS Methods for the Investigation of Polypills for the Treatment of Cardiovascular Diseases: Part.1Separation of Active Compo,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 47, 2008, pp. 508-515.
|
[6]
|
V. Kumar, S. Malik and S. Singh, “Polypill for the treatment of cardiovascular diseases: Part 2. LC-MS/TOF characterization of interaction/degradation products of atenolol/lisinopril,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 48, No. 3, 2008, pp. 619-628.
|
[7]
|
M. C. Koester, “An Overview of the Physiology and Pharmacology of Aspirin and Nonsteroidal Anti-Inflammatory Drugs,” Journal of Athletic Training, Vol. 28, No. 3, 1993, pp. 252-254, 256-259.
|
[8]
|
S. P. Clissold, “Aspirin and Related Derivatives of Salicylic Acid,” Drugs, Vol. 32, Supplement 4, 1986, pp. 8- 26.
|
[9]
|
R. G. Bakker-Arkema, M. H. Davidson, R. J. Goldstein, “Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients with Hypertriglyceri- demia,” Journal of the American Medical Association, Vol. 275, No. 2, 1996, pp. 128-133.
|
[10]
|
A. N. Wadworth, D. Murdoch, R. N. Brogden, “Atenolol: A Reappraisal of its Pharmacological Properties and Therapeutic Use in Cardiovascular Disorders,” Drugs, Vol. 42, No. 3, 1991, pp. 468-510.
|
[11]
|
B. M. Psaty, T. D. Koepsell, J. P. LoGerfo, et al., “B-Blockers and Primary Prevention of Coronary Heart Disease in Patients with High Blood Pressure,” Journal of the American Medical Association, Vol. 261, No. 14, 1989, pp. 2087-2094.
|
[12]
|
K. L. Goa and A. J. Wag, “Losartan Potassium: A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Hypertension,” Drugs, Vol. 51, No. 5, 1996, pp. 820-845.
|
[13]
|
E. R. Montgomery, S. Taylor, J. Segretario, et al., “Development and Validation of a Reversed-Phase Liquid Chromatographic Method for Analysis of Aspirin and Warfarin in a Combination Tablet Formulation,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 15, No. 1, 1996, pp. 73-82.
|
[14]
|
D. G. Sankar, M. S. M. Raju, K. Sumanth and P. V. M. Latha, “Asian HPLC Method for Estimation of Atorvastatin in Pure and Pharmaceutical Dosage Form,” Journal of Chemistry, Vol. 17, 2005, pp. 2571-2574.
|
[15]
|
S. Erturk, A. E. Sevinc, L. Ersoy and S. Ficicioglu, “HPLC Method for the Determination of Atorvastatin and its Impurities in Bulk Drug and Tablets,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, 2003, pp. 1017-1023.
|
[16]
|
A. Puratchikody, R. Valarmathy, P. Shiju, “RP-HPLC Determination of Atorvastatin Calcium in Solid Dosage Forms,” Journal of Pharmaceutical Reviews, 2003, pp. 79-80.
|
[17]
|
B. Stanisz and L. Kania, “Validation of HPLC Method for Determination of Atorvastatin in Tablets and for Monitoring in Solid Phase,” Acta Poloniae Pharmaceutica, Vol. 63, No. 6, 2006, pp. 471-476.
|
[18]
|
G. Bahrami, B. Mohammadi, S. Mirzaeei and A. Kiani, “Determination of Atorvastatin in Human Serum by Reverse Phase High Performance Liquid Chromatography with UV Detection,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 826, 2005, pp. 41-45.
|
[19]
|
M. Jemal, Z. Ouyang, B. C. Chen and D. Teitz, “Quantitation of Atorvastatin and its Bio-Transformation Products in Human Serum by HPLC with Electro Spray Tandem Mass Spectrometry,” Rapid Communications in Mass Spectrometry, Vol. 13, 1999, pp. 1003-1015.
|
[20]
|
M. Hermann, H. Christensen and J. L. Reubsaet, “Determination of Atorvastatin and Metabolites in Human Plasma with Solid Phase Extraction Followed by LC- Tandem MS,” Analytical and Bioanalytical Chemistry, Vol. 382, No. 5, 2005, pp. 1242-1249.
|
[21]
|
S. R. Dhaneshwar, S. Yadav, A. Mhaske and S. Kadam, “HPTLC Method for Determination of Content Uni- formity of Atorvastatin Calcium Tablets,” Indian Journal of Pharmaceutical Sciences, Vol. 67, 2005, pp. 182-186.
|
[22]
|
C. V. N. Prasad, C. Parihar, K. Sunil and P. Parimoo, “Simultaneous Determination of Amiloride, Hydrochloro- thiazide and Atenolol in Combined Formulation by Derivative Spectroscopy,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 17, 1998, pp. 877-884.
|
[23]
|
S. M. Al-Ghannam, “A Simple Spectrophotometric Method for the Determination of B-Blockers in Dosage Forms,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 40, No. 1, 2006, pp. 151-156.
|
[24]
|
A. P. Agrekar and S. G. Powar, “Reverse Phase High Performance Liquid Chromatographic Determination of Ramipril and Amlodipine in Tablets,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 21, 2000, pp. 1137-1142.
|
[25]
|
M. B. Shankar, F. A. Metha, K. K. Bhatt, R. S. Metha and M. Geetha, “Simultaneous Spectrophotometric Determination of Losartan Potassium and Hydrochlorothiazide in Tablets,” Indian Journal of Pharmaceutical Sciences, Vol. 65, No. 2, 2003, pp. 167-170.
|
[26]
|
C. F. Pedroso, J. G. de Oliveira, F. R. Campos, et al., “A Validated RP-LC Method for Simultaneous Determination of Losartan Potassium and Amlodipine Besilate in Pharmaceutical Preparations,” Chromatography, Vol. 69, Supplement 2, pp. 201-206.
|
[27]
|
D. D. Rao, N. V. Satyanarayana, S. S. Sait, Y. R. Reddy and K. Mukkanti, “Simultaneous Determination of Losartan Potassium, Atenolol and Hydrochlorothiazide in Pharmaceutical Preparations by Stability-Indicating UPLC,” Chromatography, Vol. 70, No. 4, 2009, pp. 647-651.
|
[28]
|
“ICH Stability Testing of New Drug Substances and Products Q1A (R2),” International Conference on Harmonization, IFPMA, Geneva, 2003.
|
[29]
|
“ICH guidelines on Validation of Analytical procedures, Text and Methodology Q2 (R1),” FDA, Published in the Federal Register 60, 1995.
|
[30]
|
“United States Pharmacopoeia,” 32nd Edition, United States Pharmacopeial Convention, Rockville, 2009.
|
[31]
|
M. Bakshi and S. Singh, “Development of Validated Stability-Indicating Assay Methods-Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-1040.
|